Blog

Trends and know-how in biotech and downstream purification.

Hydrophobic Interaction Chromatography: Understanding its principle and usage

Discover the fascinating principle behind hydrophobic interaction chromatography and how it is used in scientific research and analysis to separate biomolecules based on their hydrophobic properties.

Traditional Chinese medicine: Separation techniques that improve efficacy

Traditional Chinese medicine (TCM) is an ancient traditional medical system that has developed over thousands of years in China without recorded external influence. TCM includes various treatment...

Current trends in Advanced Therapeutic Medicinal Products (ATMPs)

Advanced therapy medicinal products (ATMPs) are human therapeutics that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease. In many ways,...

How to improve peptide purification for affordable insulin

The global diabetes pandemic has created a massive demand for insulin, especially in China, which is expected to have half the world’s diabetes patients soon. Meeting this demand means developing...

How reversing downstream bioprocess steps can make all the difference

Improving the downstream bioprocess economy depends on fine-tuning an enormous range of parameters, from culture and harvesting to purification and final polishing. Success depends on the ability to...

How diversity in peptide therapeutics can revolutionize medicine

More than 80 peptide drugs have been approved by the FDA so far, and many more are in clinical development for a wide range of diseases. Peptide drugs have substantial therapeutic potential because...

How to improve process efficiency and economy in peptide production

The purity requirements for therapeutic peptides are very stringent, but synthesis generates a crude peptide mixture containing failed sequences and chemical variants, while recombinant peptides have...

The promise and the price of the new biopharmaceuticals

The healthcare sector and developers of new pharmaceuticals are facing increasing challenges, along with pressure to lower costs. At the same time pharmaceutical development is undergoing a...

Advances in oligonucleotide therapeutics by molecular diversity

Therapeutic oligonucleotides are relatively simple molecules in the world of molecular biology. They are single- or double-stranded segments of DNA or RNA of about 10–50 nucleotides. Yet, despite...

New biopharmaceuticals on the horizon: A purification challenge

In 1982 a new type of pharmaceutical appeared on the market. Recombinant human insulin was approved for human therapeutic use and is generally acknowledged as the first “biopharmaceutical” or...

How prepacked chromatography columns help you scale up biomanufacturing faster

Chromatography is a popular purification technique used in biomanufacturing to separate and isolate your target biomolecule from the presence of impurities. To scale up the biomanufacturing process...

Pharma 4.0: Revolutionizing the Pharmaceutical Industry

Pharma 4.0, the latest buzzword in the pharmaceutical industry, has the potential to transform the industry by making the drug development process faster, more efficient, and more patient-centric. By...

Interview with Ryan MacDougall of Lonza

At BPI in Boston this September we were lucky enough to get to talk to Ryan MacDougall of Lonza and to hear about the BioPhorum group that he was representing at the conference.

Interview with Tom Ransohoff of Resilience

Another of the great meetings we had at BPI in Boston was with Tom Ransohoff of the biomanufacturing partner, Resilience and he told us something about their business and the changes he’s seen since...

Interview with Andrew Lees of FinaBio

At the BioProcess International in Boston 27-30 Sept we had the pleasure to talk to Andrew Lees, founder of Fina Biosolutions and to hear a little about their role in the field of vaccine development.

Interview with Jean Bender

At BPI Boston this year we were honored to talk to Jean Bender who has enormous experience in process development, antibodies and the industry in general.

Interview with Slim Chiha of Prosion Therapeutics

At the 2022 ACHEMA conference we had the pleasure of getting to talk to Slim Chiha, CEO and founder of Prosion Therapeutics who was participating in the Start-Up Challenge Award.

Interview with Wolfgang Winter on Pharma 4.0

We talked to Wolfgang Winter, Informatics Platform R&D Director at Agilent after his very interesting talk on the current status of Pharma 4.0 at the 2022 ACHEMA conference.

QuickTip #10: Avoiding loss of activity of Ni charged IMAC columns

Have you experienced how Nickel-charged chromatography columns used for purifying His-tagged proteins lose their blue color, become a bit yellow and can’t bind your protein anymore? It can happen...

QuickTip #9: Purifying a His-tagged protein with low expression level

Do you find yourself having to deal with a very low yield of your target protein after the expression? Are you using a His-tag? Here are some ideas to help you with your purification.

QuickTip #8: Desalting oligos for therapeutic use

If you’re purifying therapeutic oligos you’ll need to clean the desalting resins afterwards in a far higher concentration of NaOH than the usual desalting resins will tolerate. This is how to solve...

Process modelling for chromatography – how is it used?

Process modelling of chromatographic behavior, in an industrial setting, can be a useful tool in dealing with the complexities of purification process development, optimization and scale-up. It can...

QuickTip #7: Improve purity of viruses and vaccines

Changing from purification products based on synthetic polymers to agarose-based chromatography will increase the purity of the target virus.

Enhanced Capture Process - a presentation

Just before the Christmas break, Lars, Haneskog, Bio-Works R&D Director, presented a new and proven strategy for downstream processing at the New Horizons in Biologics and Bioprocessing conference....

QuickTip #6: Use true buffers

A critical and fundamental factor in both analytical and preparative chromatography is the use of true buffers. In other words, mobile phases with buffering capacity. For example, in peptide...

QuickTip #5: Filter everything

Filtering is crucial in order to protect the packed column from all solid particles in feeds or eluents. Clogging of the column will increase back-pressure and disturb the feed loading zone causing...

Ten things you must know when producing synthetic therapeutic peptides

Peptide therapeutic agents are enjoying increasing success but they are challenging to produce and, not least, to purify. Purity requirements are, in fact, approaching those for small molecules....

QuickTip #4: yield of His-tagged proteins

Immobilized Metal Ion Affinity Chromatography (IMAC) is used for purification of His-tagged proteins. Ni-NTA based resins are the most commonly used as the Ni2+ ion is considered to have the...

Join the effort to make chromatography sustainable

The environmental impact of pharmaceutical R&D and production is considerable. Although the industry is rather conservative and also constrained by regulatory guidelines, there is increasing interest...

QuickTip #3: optimizing mAb purification

Designing an optimized purification process means maximizing yield and purity, and at the same time controlling costs. So, you remove a lot of bulk impurities during the first steps, and focus on...

Affordable and safe biosimilars for affordable healthcare

When it comes to many serious and challenging diseases, healthcare has reached a point of unsustainability, due to drug costs. For example, sustained therapy for an autoimmune disease or cancer,...

Are mAbs the ultimate targeted therapy?

Since the 1980’s, monoclonal antibodies (mAbs) have revolutionized healthcare and continue to do so. A short history of mAb approvals shows their increasing sophistication and targeting of disease...

QuickTip #2: choosing IEX resin

Recovery of your biologically active target substance is a priority, and it’s important to check for its pH and ionic strength stability values...

CHO cells in fed-batch bioreactors dominate mAb upstream processes

Choosing a mammalian cell line or other type of host is as critical a question as any other in the complex world of monoclonal antibody (mAb) manufacture. We take a look at the present status, with...

QuickTip #1: cleaning IEX columns

When an IEX resin has been used for some time, impurities may build up in the column causing loss of resolution or increase in back pressure (shown on the pressure monitor or seen by gap formation on...

Illnesses with approved monoclonal antibody therapies

As our understanding of diseases at the molecular level increases, so does the potential for monoclonal antibody (mAb) - related therapies. Platform approaches to mAb production, including...

mAb Purification – an overview of the essentials

Five of the top ten best selling drugs in 2017 were mAbs and the global mAbs market is expected to reach USD 219 billion by the end of 2023. The mAbs entering the clinic today are highly engineered...

Optimizing mAb purification with next generation protein A resin

The market for monoclonal antibodies (mAbs) is constantly growing as mAb therapies are generally considered to be both safe and effective treatments for difficult diseases like cancer and rheumatoid...

Some general tips on protein purification strategy

Can you generalize about something as broad as protein purification strategy? Surely it depends on the protein and the situation in general? Well, yes, of course. But there are some general aspects...

Optimizing mAb purification using a guard column

What are the benefits of introducing multimodal ion exchange chromatography as a guard column and could they include a significant increase in mAb purity? This article presents a study in which two...

How to recognize an efficient protein A resin for mAbs

In short, an efficient protein A resin is one that will not only help you purify your monoclonal antibody (mAb), but also enable you to achieve good process economy. But what are the characteristics...

Three market changes that will impact the production of mAbs

In 2015, the monoclonal antibodies (mAbs) market was estimated to be USD 85,4 billion and predicted to reach approximately USD 130 billion in 2023[1]. However, new research points at a much higher...

How pure is pure? Controlling your mAb purification process

Monoclonal antibodies, mAbs, form a well-established, technologically advanced segment of the pharmaceutical industry offering hope for large groups of patients who have difficult-to-treat cancers,...